{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:24:31Z","timestamp":1785018271268,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jconrel.2017.09.035","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T12:01:00Z","timestamp":1506686460000},"page":"226-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis"],"prefix":"10.1016","volume":"266","author":[{"given":"Nesrine S.","family":"El-Mezayen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam F.","family":"El-Hadidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam M.","family":"El-Refaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th.I.","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman S.","family":"El-Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0005","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-12-800134-9.00003-8","article-title":"Hepatic fibrosis: a global clinical problem","author":"Pinzani","year":"2015","journal-title":"Stellate Cells Health Dis."},{"issue":"F1000 Faculty Rev","key":"10.1016\/j.jconrel.2017.09.035_bb0015","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.12688\/f1000research.8822.1","article-title":"Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis","volume":"5","author":"Dobie","year":"2016","journal-title":"F1000Research"},{"issue":"4","key":"10.1016\/j.jconrel.2017.09.035_bb0020","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3748\/wjg.v22.i4.1570","article-title":"Liver transplantation for viral hepatitis in 2015","volume":"22","author":"Ferrarese","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0025","series-title":"Seminars in Liver Disease","article-title":"Regression of liver fibrosis","year":"2017"},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.yexcr.2016.01.012","article-title":"Vitamin A and insulin are required for the maintenance of hepatic stellate cell quiescence","volume":"341","author":"Yoneda","year":"2016","journal-title":"Exp. Cell Res."},{"issue":"7","key":"10.1016\/j.jconrel.2017.09.035_bb0035","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bbadis.2012.11.002","article-title":"Extracellular matrix degradation in liver fibrosis: biochemistry and regulation","volume":"1832","author":"Iredale","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fphar.2016.00033","article-title":"Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis","volume":"7","author":"Schon","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0045","doi-asserted-by":"crossref","first-page":"e92925","DOI":"10.1371\/journal.pone.0092925","article-title":"Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis","volume":"9","author":"Hayes","year":"2014","journal-title":"PLoS One"},{"issue":"284","key":"10.1016\/j.jconrel.2017.09.035_bb0050","doi-asserted-by":"crossref","first-page":"ra58-ra","DOI":"10.1126\/scisignal.2003994","article-title":"Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks","volume":"6","author":"Wagner","year":"2013","journal-title":"Sci. Signal."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jhep.2006.04.010","article-title":"Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice","volume":"45","author":"Czochra","year":"2006","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jconrel.2017.09.035_bb0060","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/jm901132v","article-title":"Selectively nonselective kinase inhibition: striking the right balance","volume":"53","author":"Morphy","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0065","first-page":"300","article-title":"New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials","volume":"6","author":"Qu","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.jconrel.2017.09.035_bb0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0080","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1468-3083.2011.04398.x","article-title":"Anti-fibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial","volume":"27","author":"Elmholdt","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0085","series-title":"Guide for the care and use of laboratory animals","author":"Council NR","year":"1996"},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0090","first-page":"14","article-title":"Liposome: methods of preparation and applications","volume":"3","author":"Dua","year":"2012","journal-title":"Int. J. Pharm. Stud. Res."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0095","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/IJN.S60178","article-title":"Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting","volume":"9","author":"Ye","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"4","key":"10.1016\/j.jconrel.2017.09.035_bb0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.jconrel.2017.09.035_bb0105","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1007\/s11095-015-1707-1","article-title":"Cationic liposome-multi-walled carbon nanotubes hybrids for dual siPLK1 and doxorubicin delivery in vitro","volume":"32","author":"Pereira","year":"2015","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijpharm.2015.03.052","article-title":"Novel curcumin-loaded gel-core hyaluosomes with promising burn-wound healing potential: development, in-vitro appraisal and in-vivo studies","volume":"486","author":"El-Refaie","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0115","first-page":"54","article-title":"Development of UV-spectrophotometric method for the determination of Imatinib Mesylate (ITM) in bulk and formulation","volume":"6","author":"Patil","year":"2013","journal-title":"Asian J. Pharm. Clin. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2017.09.035_bb0120","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1007\/s11095-015-1672-8","article-title":"Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in-vitro optimization, ex-vivo and in-vivo permeation","volume":"32","author":"El-Refaie","year":"2015","journal-title":"Pharm. Res."},{"issue":"3\u20134","key":"10.1016\/j.jconrel.2017.09.035_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01309027","article-title":"Spectrophotometric assay of retinol via charge-transfer complexes","volume":"103","author":"Ibrahim","year":"1991","journal-title":"Microchim. Acta"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0130","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3389\/fpls.2014.00521","article-title":"Identification of Quercus agrifolia (coast live oak) resistant to the invasive pathogen Phytophthora ramorum in native stands using Fourier-transform infrared (FT-IR) spectroscopy","volume":"5","author":"Conrad","year":"2014","journal-title":"Front. Plant Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bpg.2011.02.004","article-title":"Animal models for the study of hepatic fibrosis","volume":"25","author":"Starkel","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0140","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1478-3231.2012.02806.x","article-title":"Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0975-7406.106570","article-title":"Quantitative determination of imatinib stability under various stress conditions","volume":"5","author":"Alkharfy","year":"2013","journal-title":"J. Pharm. Bioallied Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0150","first-page":"35","article-title":"HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice","volume":"23","author":"Teoh","year":"2010","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0155","series-title":"Theory and Practice of Histological Techniques","author":"Bancroft","year":"2008"},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0160","first-page":"690","article-title":"Chronic hepatitis: morphology and nomenclature","volume":"7","author":"Ishak","year":"1994","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.jconrel.2017.09.035_bb0165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases","volume":"47","author":"Goodman","year":"2007","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/ajcp\/28.1.56","article-title":"A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases","volume":"28","author":"Reitman","year":"1957","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0009-8981(96)06447-9","article-title":"Albumin standards and the measurement of serum albumin with bromcresol green","volume":"258","author":"Doumas","year":"1997","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0180","series-title":"Human Blood Coagulation and Its Disorders","author":"Biggs","year":"1962"},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0009-8981(93)90024-X","article-title":"A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase\/type IV collagenase) using monoclonal antibodies","volume":"221","author":"Fujimoto","year":"1993","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.jconrel.2017.09.035_bb0190","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/clinchem\/43.10.1965","article-title":"Immunological measurement of transforming growth factor-beta 1 (TGF-\u03b21) in blood; assay development and comparison","volume":"43","author":"Kropf","year":"1997","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0195","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0003-9861(61)90291-0","article-title":"The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid","volume":"93","author":"Woessner","year":"1961","journal-title":"Arch. Biochem. Biophys."},{"issue":"14 suppl 1","key":"10.1016\/j.jconrel.2017.09.035_bb0200","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1161\/CIRCULATIONAHA.107.740613","article-title":"Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation","volume":"118","author":"Kimura","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0205","first-page":"1082","volume":"2","author":"Thampi","year":"2014","journal-title":"Indian J. Res. Pharm. Biotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1536\/ihj.14-338","article-title":"Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension","volume":"56","author":"Akagi","year":"2015","journal-title":"Int. Heart J."},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0215","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.bbamem.2007.03.027","article-title":"A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats","volume":"1768","author":"Adrian","year":"2007","journal-title":"Biochim. Biophys. Biomembr."},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jconrel.2011.12.023","article-title":"Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor\u2013beta on hepatic fibrosis in rats","volume":"159","author":"Li","year":"2012","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2017.09.035_bb0225","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jhep.2005.04.014","article-title":"Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell","volume":"43","author":"Greupink","year":"2005","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0230","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s11095-006-9175-2","article-title":"Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated","volume":"24","author":"Hagens","year":"2007","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0235","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1096\/fj.14-258459","article-title":"Selective delivery of IFN-\u03b3 to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis","volume":"29","author":"Poosti","year":"2015","journal-title":"FASEB J."},{"issue":"11","key":"10.1016\/j.jconrel.2017.09.035_bb0240","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1158\/1535-7163.MCT-11-0758","article-title":"Selective targeting of interferon \u03b3 to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth","volume":"11","author":"Bansal","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2010.03.018","article-title":"A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier","volume":"145","author":"Prakash","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0250","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2014.02.004","article-title":"Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications","volume":"180","author":"Elnaggar","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","article-title":"Nanotechnology-based drug delivery systems for Alzheimer's disease management: technical, industrial, and clinical challenges","volume":"245","author":"Wen","year":"2016","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2017.09.035_bb0260","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1164\/rccm.200702-178OC","article-title":"Role of \u03b11-acid glycoprotein in therapeutic anti-fibrotic effects of imatinib with macrolides in mice","volume":"176","author":"Azuma","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0265","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.3892\/mmr.2015.3842","article-title":"Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro","volume":"12","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"17","key":"10.1016\/j.jconrel.2017.09.035_bb0270","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1093\/emboj\/18.17.4633","article-title":"Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein","volume":"18","author":"Quadro","year":"1999","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.jconrel.2017.09.035_bb0275","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1194\/jlr.M400137-JLR200","article-title":"The role of extrahepatic retinol binding protein in the mobilization of retinoid stores","volume":"45","author":"Quadro","year":"2004","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0280","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1039\/C4TB01611D","article-title":"Diagnostic imaging and therapeutic application of nanoparticles targeting the liver","volume":"3","author":"Wang","year":"2015","journal-title":"J. Mater. Chem. B"},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2012.02.011","article-title":"Drug targeting to the diseased liver","volume":"161","author":"Poelstra","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0290","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00926084","article-title":"Influence of liposome charge and composition on their interaction with human blood serum proteins","volume":"120","author":"Hern\u00e1ndez-Caselles","year":"1993","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chemphyslip.2006.01.008","article-title":"Study and formation of vesicle systems with low polydispersity index by ultrasound method","volume":"140","author":"Pereira-Lachataignerais","year":"2006","journal-title":"Chem. Phys. Lipids"},{"issue":"5","key":"10.1016\/j.jconrel.2017.09.035_bb0300","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/17425247.2011.566552","article-title":"Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity","volume":"8","author":"Gubernator","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0305","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0005-2736(88)90399-9","article-title":"NMR study of the interaction of retinoids with phospholipid bilayers","volume":"946","author":"De Boeck","year":"1988","journal-title":"Biochim. Biophys. Act Biomembr."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0310","first-page":"765","article-title":"Recent advances of chitosan nanoparticles as drug carriers","volume":"6","author":"Wang","year":"2011","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0315","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijpharm.2006.03.040","article-title":"Retinol-encapsulated low molecular water-soluble chitosan nanoparticles","volume":"319","author":"Kim","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0320","series-title":"Encyclopedia of Analytical Chemistry","article-title":"Interpretation of infrared spectra, a practical approach","author":"Coates","year":"2000"},{"issue":"15","key":"10.1016\/j.jconrel.2017.09.035_bb0325","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1093\/nar\/gkp543","article-title":"Structural characterization of cationic lipid\u2013tRNA complexes","volume":"37","author":"Marty","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"36","key":"10.1016\/j.jconrel.2017.09.035_bb0330","doi-asserted-by":"crossref","first-page":"10839","DOI":"10.1021\/jp072890b","article-title":"Retinoid chromophores as probes of membrane lipid order","volume":"111","author":"Svensson","year":"2007","journal-title":"J. Phys. Chem. B"},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0335","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0005-2736(88)90085-5","article-title":"Electron spin resonance study of the interactions of retinoids with a phospholipid model membrane","volume":"939","author":"Wassall","year":"1988","journal-title":"Biochim. Biophys. Act Biomembr."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0340","series-title":"Retinoids","first-page":"3","article-title":"Physical-chemical properties and action of retinoids","author":"Noy","year":"1999"},{"issue":"5","key":"10.1016\/j.jconrel.2017.09.035_bb0345","doi-asserted-by":"crossref","first-page":"G729","DOI":"10.1152\/ajpgi.00013.2011","article-title":"Animal models for the study of liver fibrosis: new insights from knockout mouse models","volume":"300","author":"Hayashi","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0350","series-title":"Experimental liver fibrosis research: update on animal models, legal issues and translational aspects","author":"AST","year":"2013"},{"issue":"4","key":"10.1016\/j.jconrel.2017.09.035_bb0355","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2183\/pjab.82.155","article-title":"Hepatic stellate cells: three-dimensional structure, localization, heterogeneity and development","volume":"82","author":"Wake","year":"2006","journal-title":"Proc. Jpn Acad. Ser. B"},{"issue":"4","key":"10.1016\/j.jconrel.2017.09.035_bb0360","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3748\/wjg.v22.i4.1348","article-title":"Hepatic non-parenchymal cells: master regulators of alcoholic liver disease?","volume":"22","author":"Seo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0365","first-page":"72","article-title":"Targeted therapies in liver fibrosis: combining the best parts of platelet derived growth factor BB and interferon gamma","volume":"2","author":"Fv","year":"2015","journal-title":"Front. Med."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0370","series-title":"Development of Therapeutic Agents Handbook","author":"Gad","year":"2011"},{"issue":"5","key":"10.1016\/j.jconrel.2017.09.035_bb0375","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","article-title":"Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH Study","volume":"16","author":"Cortes","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0380","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs","volume":"25","author":"Darkow","year":"2007","journal-title":"PharmacoEconomics"},{"issue":"12","key":"10.1016\/j.jconrel.2017.09.035_bb0385","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR\u2013ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0390","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tox.2017.03.006","article-title":"Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity","volume":"382","author":"Chambers","year":"2017","journal-title":"Toxicology"},{"issue":"11","key":"10.1016\/j.jconrel.2017.09.035_bb0395","first-page":"824","article-title":"Pulmonary toxicities of tyrosine kinase inhibitors","volume":"9","author":"Peerzada","year":"2011","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0400","series-title":"Handbook of Acute Leukemia","first-page":"65","article-title":"Therapeutic management of acute lymphoblastic leukemia","author":"Spiekermann","year":"2016"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0405","first-page":"5","article-title":"Transactivation of platelet-derived growth factor receptor type \u03b2: mechanisms and potential relevance in","author":"Kruk","year":"2013","journal-title":"Neurobiology"},{"key":"10.1016\/j.jconrel.2017.09.035_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3529149","article-title":"liver enzyme release really associated with cell necrosis induced by oxidant stress?","volume":"2016","author":"Contreras-Zentella","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0415","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3889\/oamjms.2016.092","article-title":"New era for usage of serum liver enzymes as a promising horizon for the prediction of non-alcoholic fatty liver disease","volume":"4","author":"Salman","year":"2016","journal-title":"Open Access Macedonian J. Med. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2017.09.035_bb0420","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/cmaj.1040752","article-title":"Liver enzyme alteration: a guide for clinicians","volume":"172","author":"Giannini","year":"2005","journal-title":"Can. Med. Assoc. J."},{"issue":"41","key":"10.1016\/j.jconrel.2017.09.035_bb0425","doi-asserted-by":"crossref","first-page":"67650","DOI":"10.18632\/oncotarget.11767","article-title":"Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"issue":"48","key":"10.1016\/j.jconrel.2017.09.035_bb0430","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3748\/wjg.v13.i48.6608","article-title":"Imatinib-induced fatal acute liver failure","volume":"13","author":"Ridruejo","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0435","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejphar.2011.08.041","article-title":"Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis","volume":"670","author":"Shaker","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0440","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1478-3231.2012.02806.x","article-title":"Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0445","doi-asserted-by":"crossref","first-page":"9713","DOI":"10.1038\/srep09713","article-title":"Potent effects of dioscin against liver fibrosis","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0450","doi-asserted-by":"crossref","first-page":"d793","DOI":"10.2741\/A812","article-title":"Roles of TGF-beta in hepatic fibrosis","volume":"7","author":"Gressner","year":"2002","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jconrel.2017.09.035_bb0455","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.matbio.2015.01.004","article-title":"Matrix metalloproteinases in liver injury, repair and fibrosis","volume":"44","author":"Duarte","year":"2015","journal-title":"Matrix Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0460","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-5926-6-9","article-title":"Establishment of an early liver fibrosis model by the hydrodynamics-based transfer of TGF-\u03b21 gene","volume":"6","author":"Yang","year":"2007","journal-title":"Comp. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2017.09.035_bb0465","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-5926-6-7","article-title":"Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options","volume":"6","author":"Gressner","year":"2007","journal-title":"Comp. Hepatol."},{"issue":"2","key":"10.1016\/j.jconrel.2017.09.035_bb0470","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/jhep.2001.21996","article-title":"Expression and matrix deposition of latent transforming growth factor \u03b2 binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture","volume":"33","author":"Breitkopf","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jconrel.2017.09.035_bb0475","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.510260620","article-title":"Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers","volume":"26","author":"Takahara","year":"1997","journal-title":"Hepatology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917308696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917308696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T13:07:52Z","timestamp":1603026472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917308696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":95,"alternative-id":["S0168365917308696"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.035","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}